Veeva Systems Inc. (VEEV) $186.24
Veeva Systems is currently trading at a 40% discount from its yearly highs, leaving investors to wonder if the cloud leader has lost its luster or is simply coiled for a massive spring back to $244.
52-wk High $310.5
📌 Investment Snapshot
- Trading at $186.24 with a 33.0x P/E, a notable compression from historical premiums.
- Latest Q1 revenue hit $0.88B with $1.60 EPS, showing steady high-single-digit growth.
- Institutional heavyweights like Blackrock and Vanguard hold over 18M combined shares.
- Consensus target of $244.14 implies a massive 31.1% runway for patient capital.
⏳ WAIT
Veeva sits in a precarious technical spot despite strong fundamental cash flows of $1.1B. The stock remains pinned below its 200-day moving average, suggesting the path of least resistance is still sideways.
| 📍 Entry Zone | $178 or below | 🛑 Stop-Loss | $168 |
| 📋 Adjust If | Price reclaims and holds $207 (SMA200) on high volume. | ||
The Investment Case — Why Now?
Over the last 90 days, Veeva has transitioned from a free-fall state to a constructive basing phase above the $170 level. While revenue growth has moderated compared to the hyper-growth years, the company’s shift to the Vault CRM platform is beginning to manifest in improved free cash flow margins. This transition is a double-edged sword that creates short-term noise but secures long-term ecosystem dominance.
The primary risk remains the high 10-year Treasury yield of 4.68%, which continues to pressure the valuations of high-multiple software-as-a-service (SaaS) names. If the macro environment shifts toward a ‘higher for longer’ rate regime, Veeva’s 33x P/E could see further compression toward the 28x level. Do you believe Veeva’s proprietary data moat is strong enough to offset the valuation headwinds posed by rising interest rates?
🤔 Do you believe Veeva’s proprietary data moat is strong enough to offset the valuation headwinds posed by rising interest rates?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Health Information Services |
| Employees | 7,000+ |
| Headquarters | Pleasanton, CA |
Open chart on TradingView →
📈 Price Action & Technicals
Dead Cross
Inside VA
Buy-side sweep at $182.09 on 2026-07-23
The price action is currently sandwiched between the SMA50 at $173.84 and the SMA200 at $206.22. This range-bound behavior confirms a lack of institutional conviction in either direction for the immediate term.
While the RSI at 44.2 is neutral, the MACD has recently printed a bearish cross below its signal line. This divergence suggests that the recent 15% bounce may be losing steam as it approaches the bearish Fair Value Gap (FVG) at $187.30.
The Anchored VWAP from the April low sits at $169.71, aligning perfectly with the Volume Profile Point of Control (POC). This $169-$170 zone represents the ‘line in the sand’ for bulls to defend at all costs.
A high ADX of 44.6 indicates a strong existing trend, but the -DI sitting above the +DI confirms that the dominant trend remains bearish. We need to see these lines flip before calling a definitive bottom.
Recent liquidity sweeps at $182.09 suggest that smart money is hunting for sell-side liquidity to fuel a potential move higher. However, the unfilled bearish FVGs up to $191.24 act as heavy overhead resistance that will likely require a catalyst to breach.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| VEEV | Veeva Systems | 33.0x |
| CRM | Salesforce | 28.5x |
| AZPN | Aspen Technology | 31.2x |
| SPY | S&P 500 Avg | 22.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $0.88B | $1.60 | +11% |
| Q4 2025 | $0.84B | $1.49 | +10% |
| Q3 2025 | $0.81B | $1.44 | +9% |
| Q2 2025 | $0.79B | $1.23 | +8% |
Veeva generated a robust $1.1B in Free Cash Flow in the latest quarter, utilizing $0.2B for strategic share buybacks to support the stock price.
Revenue growth has stabilized in the 8-11% range, a significant slowdown from the 20%+ levels seen in 2022. However, the expansion of EPS from $1.23 to $1.60 over four quarters demonstrates impressive operational leverage and cost discipline.
🚀 Growth Drivers — What Moves the Stock
- Vault CRM Migration 🟢 Upside Surprise — The transition of customers to Veeva’s own CRM platform reduces third-party licensing costs and boosts long-term margins.
- Compass Data Suite 🟡 Priced In — New data products for the pharmaceutical industry are seeing early adoption, though full revenue impact is likely 12-18 months away.
🤔 Can Veeva successfully transition its entire user base to Vault CRM without significant churn to cheaper competitors?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 11,558 |
| Vanguard Portfolio Management | 7,376 |
| Alliancebernstein L.P. | 6,271 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| SCHWENGER THOMAS D | President | 2026-07-16 | Sale | 5000 |
| VAN WAGENER BRIAN | CFO | 2026-07-01 | Sale | 1635 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 5.3% | 3.2 |
⚠ Key Risk Factors
~$2B impact
~$4B impact
🎯 Guidance & Wall Street View
Management expects continued margin expansion as the Vault platform scales, though they remain cautious on the macro spending environment for life sciences.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $350.00 | $244.14 | $165.00 | 28 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Guggenheim | Buy | $244 | 2026-07-23 | Initiated |
| Goldman Sachs | Sell | $170 | 2026-06-04 | Maintained |
While the mean target suggests 31% upside, the wide $185 gap between high and low targets indicates significant disagreement on Veeva’s terminal growth rate.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Vault CRM adoption exceeds expectations, driving 40%+ FCF margins.
- Fed begins rate cut cycle, triggering a massive rotation back into high-quality SaaS.
📊 Base Case
Veeva continues to grow revenue at 10% while slowly regaining its valuation premium as macro fears subside.
🐻 Bear Case
- Competition from generic cloud providers eats into market share.
- Macro slowdown leads to longer sales cycles in the biotech sector.
🎯 Investor Action Plan — By Profile
The stock is currently testing a bearish FVG at $187. Wait for a rejection and a retest of the $178 bullish FVG for a better risk/reward entry.
Despite the high Confluence Score of 90, the price remains below the SMA200. Patience is required until the trend officially shifts to bullish.
The fundamental story is intact with $1.1B in FCF. Continue to hold but avoid adding new capital until the macro environment stabilizes.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is VEEV stock down 40% from its high?
A combination of slowing revenue growth and a general market rotation away from high-multiple SaaS stocks due to rising interest rates.
Q: What is the key support level for Veeva?
The $169-$170 zone is critical, as it aligns with the Volume Profile POC and the Anchored VWAP from the April lows.
Q: Is the dividend yield attractive?
Veeva does not currently pay a dividend, focusing instead on share buybacks and reinvesting in its cloud platform.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. The author has no position in VEEV at the time of writing.
All active positions and their real-time performance are tracked on our Investment Log.
#VEEV #VeevaSystems #SaaS #HealthTech #StockMarket #Investing #TechnicalAnalysis